Download now Free registration required
Until recently, the commercial and financial performance of drug development companies has been one to which many other sectors aspired. Pharmaceutical stocks during the 1990's were considered a safe haven for investors, whatever else was happening in the market. This has changed dramatically over the last five years, as this sector has become one of the few that has seen contraction in real corporate value, in terms of market capitalization and stock returns. A key reason for this decline is the increasingly poor performance of the sector in getting new drugs to market.
- Format: PDF
- Size: 112.6 KB